Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130578) titled 'The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer' on Aug. 12.

Study Type: Observational

Primary Sponsor: Tianjin Medical University Second Hospital

Condition: Bladder Cancer Liquid Biopsy

Intervention: Diagnostic Test: urine tumor DNA/RNA testing

Recruitment Status: Recruiting

Date of First Enrollment: May 1, 2025

Target Sample Size: 60

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07130578

Published by HT Digital Content Services with permission from Health ...